Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics

Arrowhead Pharmaceuticals, Inc. (ARWR)

Today's Latest Price: $57.30 USD

0.79 (-1.36%)

Updated Oct 30 4:00pm

Add ARWR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ARWR Stock Summary

  • With a price/sales ratio of 47.4, Arrowhead Pharmaceuticals Inc has a higher such ratio than 95.8% of stocks in our set.
  • ARWR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 11.82% of US stocks.
  • Over the past twelve months, ARWR has reported earnings growth of -182.7%, putting it ahead of just 10.56% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arrowhead Pharmaceuticals Inc are CUE, BLUE, ARVN, ZYME, and ACRS.
  • ARWR's SEC filings can be seen here. And to visit Arrowhead Pharmaceuticals Inc's official web site, go to

ARWR Stock Price Chart Interactive Chart >

Price chart for ARWR

ARWR Price/Volume Stats

Current price $57.30 52-week high $73.72
Prev. close $58.09 52-week low $19.51
Day low $55.57 Volume 1,039,400
Day high $58.58 Avg. volume 1,470,844
50-day MA $45.54 Dividend yield N/A
200-day MA $39.86 Market Cap 5.86B

Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio

Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.

ARWR Latest News Stream

Event/Time News Detail
Loading, please wait...

ARWR Latest Social Stream

Loading social stream, please wait...

View Full ARWR Social Stream

Latest ARWR News From Around the Web

Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Global RNA Interference Market To See Astonishing Growth By 2027|Covid 19 Impact Analysis By Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals

This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of

OpenPR | September 30, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference

Business Wire | September 30, 2020

INO, ARWR, ADT and AXL among midday movers

Gainers: Arrowhead Pharmaceuticals (ARWR) +47%.Eastman Kodak (KODK) +39%.Myomo (MYO) +35%.Inovio Pharmaceuticals (INO) +27%.Renren (RENN) +25%.AMC Networks (AMCX) +22%.Pacific Ethanol (PEIX) +22%.Histogen (HSTO) +21%.Heat Biologics (HTBX) +16%.Ossen Innovation (OSN) +16%.Losers: Novus Therapeutics (NVUS) -17%.ADT (ADT) -13%.American Axle & Manufacturing (AXL) -12%.Forterra (FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (FRAN) -10%.Grupo Supervielle (SUPV) -9%.89bio (ETNB) -9%.Jounce Therapeutics (JNCE) -9%.Empresa Distribuidora (EDN) -6%....

Seeking Alpha | September 16, 2020

Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers

Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%....

Seeking Alpha | September 16, 2020

Why Arrowhead Pharma's Stock Is Trading Higher Today

Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in …

Benzinga | September 16, 2020

Read More 'ARWR' Stories Here

ARWR Price Returns

1-mo 28.02%
3-mo 33.04%
6-mo 67.74%
1-year 38.14%
3-year 1,532.48%
5-year 971.03%
YTD -9.66%
2019 410.71%
2018 237.50%
2017 137.42%
2016 -74.80%
2015 -16.67%

Continue Researching ARWR

Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7424 seconds.